XSpray Pharma AB
Xspray Pharma AB (publ), a pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden. The company develops Dasynoc, an amorphous version of dasatinib for the treatment of chronic myeloid leukemia (CML)and acute lymphoblastic leukemia; XS003, an amorphous non-crystalline nilotinib for the treatment of CML; XS008, an axitinib for the tr… Read more
XSpray Pharma AB (XSPRAY) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.064x
Based on the latest financial reports, XSpray Pharma AB (XSPRAY) has a cash flow conversion efficiency ratio of -0.064x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-41.35 Million) by net assets (Skr641.73 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
XSpray Pharma AB - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how XSpray Pharma AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
XSpray Pharma AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of XSpray Pharma AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Himatsingka Seide Limited
NSE:HIMATSEIDE
|
0.086x |
|
Lassila &Tikanoja Oyj
HE:LAT1V
|
0.070x |
|
CI Games SA
WAR:CIG
|
0.044x |
|
INTRON TECH.HLDGS HD -01
F:B46
|
N/A |
|
Alterity Therapeutics Ltd
NASDAQ:ATHE
|
-0.192x |
|
Harrisons Holdings (Malaysia)
KLSE:5008
|
0.095x |
|
Carlo Gavazzi Holding AG
SW:GAV
|
0.010x |
|
Cupid Limited
NSE:CUPID
|
0.061x |
Annual Cash Flow Conversion Efficiency for XSpray Pharma AB (2015–2024)
The table below shows the annual cash flow conversion efficiency of XSpray Pharma AB from 2015 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr623.10 Million | Skr-222.37 Million | -0.357x | -21.74% |
| 2023-12-31 | Skr693.41 Million | Skr-203.28 Million | -0.293x | -47.94% |
| 2022-12-31 | Skr556.02 Million | Skr-110.18 Million | -0.198x | -127.22% |
| 2021-12-31 | Skr591.75 Million | Skr-51.61 Million | -0.087x | -6.31% |
| 2020-12-31 | Skr582.59 Million | Skr-47.79 Million | -0.082x | +10.46% |
| 2019-12-31 | Skr373.71 Million | Skr-34.24 Million | -0.092x | -55.76% |
| 2018-12-31 | Skr301.72 Million | Skr-17.75 Million | -0.059x | +17.07% |
| 2017-12-31 | Skr155.66 Million | Skr-11.04 Million | -0.071x | -89.00% |
| 2016-12-31 | Skr46.47 Million | Skr-1.74 Million | -0.038x | +96.45% |
| 2015-12-31 | Skr12.26 Million | Skr-12.96 Million | -1.057x | -- |